UK showcases high-performance delivery in time-critical Norovirus trial

The UK has demonstrated its capability to deliver high-volume recruitment within time-sensitive windows, exceeding targets for Cohort 3 of Moderna’s Nova 301 Norovirus vaccine trial. Highlighting major improvements in system agility, 30 UK sites – majority within the NHS – recruited over 2,500 volunteers in just 65 days. This coordinated effort secured 25% of total global recruitment for this cohort, reinforcing the UK’s position as a predictable, high-performance destination for commercial life sciences trials.